Beta-blocker therapy cuts all-cause mortality in STEMI
Jeong Hoon Yang, M.D., from Samsung Medical Center in Seoul, South Korea, and colleagues examined the correlation of beta-blocker therapy at discharge with clinical outcomes using data from 8,510 patients with STEMI undergoing primary PCI. Patients were classified into a beta-blocker group (6,873 patients) and no-beta-blocker group (1,637 patients). Propensity-score matching analysis was conducted in 1,325 patient triplets. Patients were followed for a median of 367 days for the primary outcome of all-cause death.
The researchers found that all-cause death occurred in 2.1 percent of the beta-blocker group and 3.6 percent of the no-beta-blocker group (P < 0.001). Beta-blocker therapy correlated with lower incidence of all-cause death after 2:1 propensity-score matching (2.8 versus 4.1 percent; adjusted hazard ratio, 0.46; P = 0.004). In terms of all-cause death, the correlation of beta-blocker therapy with better outcomes was consistent across subgroups, including patients with relatively low-risk profiles such as ejection fraction >40 percent or single-vessel disease.
"Our results support the current American College of Cardiology/American Heart Association guidelines, which recommend long-term beta-blocker therapy in all patients with STEMI regardless of reperfusion therapy or risk profile," the authors write.
Copyright © 2014 HealthDay. All rights reserved.